IN8bio (INAB) said Tuesday that new data from the ongoing early-stage study of INB-100 showed that 100% of acute myeloid leukemia patients in the original and expansion groups through Jan. 17 remained in complete remission.
The company said INB-100, which is designed to help patients with complex leukemias, such as AML, also showed improved survival compared with standard treatment.
The investigational therapy also "appears to be well-tolerated" and has no significant effect on patient quality of life, the company said.
Shares of IN8bio were up 71% in recent premarket activity on Tuesday.
Price: 0.4797, Change: +0.21, Percent Change: +77.60
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.